SHANGHAI – In the almost two years since Chinese police said they were investigating Glaxosmithkline plc for corruption, the industry here has seen compliance go from a mid-level priority, second to meeting ambitious sales targets, to a board-level issue directly concerning senior management teams and those legally responsible for the business.
SHANGHAI – Astrazeneca plc, of London, inked an academic collaboration with leading Singaporean research institutes to take advantage of a unique feature of the small but diverse city-state: access to a population that can provide insights into heart failure.
SHANGHAI – Astrazeneca plc, of London, inked an academic collaboration with leading Singaporean research institutes to take advantage of a unique feature of the small but diverse city-state: access to a population that can provide insights into heart failure.
SHANGHAI – Hutchison Medipharma Ltd. (HMP) has gone from running a marathon to a sprint. HMP's pipeline has quickly grown from seven clinical trials to 16, 13 of which are phase Ib/II studies with 10 being in potential breakthrough therapy indications. This spurt of activity now puts HMP much closer to the finish line to deliver China's first world-class drug since artemisinin, an antimalarial that was discovered decades ago.
SHANGHAI – Hutchison Medipharma Ltd. (HMP) has gone from running a marathon to a sprint. HMP's pipeline has quickly grown from seven clinical trials to 16, 13 of which are phase Ib/II studies with 10 being in potential breakthrough therapy indications.
SHANGHAI – A trans-Pacific biotech – with labs in Zhangjiang Hi-tech Park in Shanghai, and offices in Hayward, Calif. – Micurx Pharmaceuticals Inc., has commenced enrollment for its U.S. phase II trial for MRX-1, an antibiotic to combat drug-resistant infections.
SHANGHAI – Six months after London-based Glaxosmithkline plc officially apologized to the Chinese government for bribing non-government personnel, a GSK spokesperson confirmed to BioWorld Asia that more than 100 employees have left the China office for violating the company's code of conduct.
SHANGHAI – Six months after London-based Glaxosmithkline plc officially apologized to the Chinese government for bribing non-government personnel, a GSK spokesperson confirmed to BioWorld Today that more than 100 employees have left the China office for violating the company's code of conduct.
SHANGHAI – A trans-Pacific biotech – with labs in Zhangjiang Hi-tech Park in Shanghai, and offices in Hayward, Calif. – Micurx Pharmaceuticals Inc., has commenced enrollment for its U.S. phase II trial for MRX-1, an antibiotic to combat drug-resistant infections.
SHANGHAI – The evolving story of CASI Pharmaceuticals Inc. is about a Nasadaq-listed firm hoping for a fresh start as a China-focused oncology company without letting go of its American roots.
